You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Emerging Immunologic Therapies for Multiple Sclerosis: Impact on Managed Care & Specialty Pharmacy

  • Authors: Erin M. Lopata, PharmD, MPH, Activity Chair; Thomas P. Leist, MD, PhD; Rebekah H. Anguiano, PharmD, BCPS, BCACP
  • CE Released: 6/19/2019
  • Valid for credit through: 6/19/2020
Start Activity

Target Audience and Goal Statement

This activity is designed to meet the educational needs of managed care specialty pharmacists, pharmacy directors, clinical pharmacists, medical directors, and Pharmacy and Therapeutics Committee pharmacists and other managed healthcare professionals involved in the management of patients with multiple sclerosis (MS).

Recent advances in the field of neuroimmunology are re-shaping the conceptualization of MS, with potential implications of new agents within the current landscape of treatment options. This symposium will examine the crucial role of managed care pharmacists in MS disease management programs, especially as new immune-directed agents emerge in the application of current evidence-based diagnoses, guidelines, and pharmacy-based managed care best practices in reducing the clinical and economic burdens related to this complex chronic disorder while optimizing patient outcomes.

Upon completion of this activity, participants will be able to:

  1. Discuss characteristics of current and emerging MS therapies, including mechanisms of action, dosage and administration, adverse effects, and drug interactions
  2. Describe the immune-mediated mechanisms of MS that may serve as immune targets for therapeutic interventions
  3. Explain the relationship between medication adherence and MS disease control, and potential strategies for overcoming barriers to adherence
  4. Review how a pharmacy-based practice model fosters increased accessibility, convenience, patient confidence, and ultimately, improved patient outcomes by incorporating specialty medication management into transitions in care, admission and discharge quality indicators, readmissions, and other quality care measures
  5. Illustrate how pharmacists, by serving as the regular point of contact, can encourage improved compliance, appropriate medication use, and provide ongoing safety monitoring, for quicker interventions


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


  • Erin M. Lopata, PharmD, MPH, Activity Chair

    Manager, Clinical Pharmacy, Residency Program Director for Managed Care, University of Pittsburgh Medical Center Health Plan, Pittsburgh, Pennsylvania


    Disclosure: Erin M. Lopata, PharmD, MPH, has no relevant financial disclosures to report.

  • Thomas P. Leist, MD, PhD

    Chief, Division of Clinical Neuroimmunology, Director, Comprehensive Multiple Sclerosis Center, Thomas Jefferson University, Philadelphia, Pennsylvania


    Disclosure: Thomas P. Leist, MD, PhD, has disclosed the following relevant financial relationships:
    Served as a consultant/ speaker for: Biogen, EMD Serono, Genentech, Novartis, Teva
    Received research/clinical trial support from: : Actelion, Alkermes, Biogen, Chugai/Roche, Novartis
    Serves as a Chair for: MSBase Foundation Board.

  • Rebekah H. Anguiano, PharmD, BCPS, BCACP

    Clinical Assistant Professor, Pharmacy Practice, Clinical Pharmacist, Ambulatory Pharmacy Services, Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois


    Disclosure: Rebekah H. Anguiano, PharmD, BCPS, BCACP, has disclosed the following relevant financial relationships:
    Received honoraria or consultation fee from: United Therapeutics
    Participated in a company sponsored speaker’s bureau for: United Therapeutics.

Accreditation Statements



In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Letters & Sciences. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Nurses

  • Letters & Sciences is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission (ANCC) on Accreditation.

    This activity is designated for 1.5 contact hours. The audience is advised that the educational content contained herein was developed by and reflects the opinions of the presenters and faculty and does not necessarily reflect the opinions or recommendations of the CE provider or the grantor. Accredited status does not imply endorsement by the provider of any commercial products discussed/displayed in conjunction with the educational activity

    Contact Provider

    For Pharmacists

  • The Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

    Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hour(s) (0.15 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - JA4008162-9999-19-827-H01-P)

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 80% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. In addition, you must complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Emerging Immunologic Therapies for Multiple Sclerosis: Impact on Managed Care & Specialty Pharmacy

Authors: Erin M. Lopata, PharmD, MPH, Activity Chair; Thomas P. Leist, MD, PhD; Rebekah H. Anguiano, PharmD, BCPS, BCACPFaculty and Disclosures

CE Released: 6/19/2019

Valid for credit through: 6/19/2020


Before you begin, please answer the questions in this brief questionnaire.

  • Print